-
EBMT China’s Voice | Professor Chunfu Li ‘s Team: Relationship between Immune Reconstitution, Graft-versus-Host Disease, and Viral Infections in Patients with Beta-Thalassemia Major Treated with Different Sources of Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is the classical treatment for curing beta-thalassemia major. With the continuous maturity of HSCT technology and supportive therapy over the past two decades, the choice of HSCT methods has expanded from classical matched sibling donor transplantation to matched unrelated donor transplantation and haploidentical transplantation. The commonly used stem cell…
-
Professor Zhongxing Jiang: Focusing on the diagnosis and treatment of chronic disease-related anemia to improve patient quality of life | The 19th National Conference on Red Blood Cell Diseases (Anemia) by the Chinese Medical Association
Chronic disease-related anemia, as one of the most common types of anemia, is the most common type of anemia among hospitalized patients and elderly individuals. Chronic disease-related anemia is usually accompanied by underlying diseases, with complex causes and diverse symptoms, distributed across multiple departments. Clinical doctors should pay sufficient attention to it in order to…
-
EBMT China’s Voice | Professor Yue Lu: Haploidentical Hematopoietic Stem Cell Transplantation Using Non-Direct Related Donors vs. Direct Related Donors – Similarity in Efficacy and Safety
In recent years, haploidentical donor hematopoietic stem cell transplantation has gradually been developed in malignant hematologic tumors, greatly solving the problem of previous donor shortages. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, the third-largest city in the UK.…
-
EBMT China’s Voice | Professors XiaoyanKe and KaiHu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year’s conference,…
-
Application of JAK1 Inhibitors in Peripheral T-cell Lymphoma: Highlights from the 15th Chinese Medical Association Hematology Academic Conference and the First Rare Blood Disease Academic Conference
From March 23rd to 24th, 2024, the 15th Chinese Medical Association Hematology Academic Conference and the First Rare Blood Disease Academic Conference, hosted by the Chinese Medical Association and the Hematology Branch of the Chinese Medical Association, and co-organized by the First Affiliated Hospital of Soochow University, was successfully held in Suzhou, Jiangsu Province, China.…
-
SABCS Voice of China | Professors Qiang Liu and Yaping Yang: Final Results of the National Multicenter Clinical Study on AC*4 Sequential T*4 Combined with Full-Course Dual-Target Neoadjuvant Treatment for HER2-Positive Breast Cancer Disclosed
Led by Professor Qiang Liu and Professor Yaping Yang from the Sun Yat-sen Memorial Hospital’s Breast Tumor Hospital at Sun Yat-sen University, the final clinical study results of a new neoadjuvant treatment regimen for HER2-positive breast cancer were disclosed for the first time. The results were presented in the form of a POSTER at the…
-
SABCS Voice of China | Teams led by Professors Yuanting Gu and Jingruo Li Announce Results of CDK4/6 Inhibitor Combined with Letrozole as Neoadjuvant Treatment for Early or Locally Advanced HR+/HER2- Breast Cancer
The results of a single-arm, multicenter, prospective exploratory clinical study on the neoadjuvant treatment of HR-positive, HER2-negative (HR+/HER2-) breast cancer with Dalpiciclib combined with Letrozole, led by Professor Yuanting Gu and Professor Jingruo Li from the First Affiliated Hospital of Zhengzhou University, were selected for poster presentation at the 2023 SABCS conference. The unveiling of…
-
SABCS Voice of China丨Professor Jian Zhang: Orally Administered SERD That Can Cross the Blood-Brain Barrier Challenges the Dilemma of Endocrine Treatment for ER+/HER2- Advanced Breast Cancer
The 46th San Antonio Breast Cancer Symposium (SABCS), a prestigious academic event in the field of international breast cancer, was held from December 5th to 9th in San Antonio, Texas, USA. A Phase I clinical study of a new selective estrogen receptor degrader (SERD) led by Professor Jiong Wu and Professor Jian Zhang ‘s team…
Connecting Medical Expertise through Media